FGFR1 and non-small cell lung carcinoma: However, most early-phase clinical trials with FGFRis have shown only a partial response, which may be a result of the poor predictive power of FGFR1 amplification, which was initially the only predictive biomarker of response to FGFRis in Sq-NSCLC [7,8,9,10,11].